Oruka Therapeutics (ORKA) Common Equity (2010 - 2026)

Oruka Therapeutics' Common Equity history runs 17 years deep, the most recent figure standing at $486.7 million for Q1 2026.

• In Q1 2026, Common Equity rose 33.45% year-over-year to $486.7 million; the TTM figure through Mar 2026 stood at $486.7 million (up 33.45% YoY), while the FY2025 annual figure was $471.9 million, up 23.47% from the prior year.
• Common Equity was $486.7 million for Q1 2026 at Oruka Therapeutics, up from $471.9 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $486.8 million in Q3 2025 to a low of -$29.0 million in Q2 2024.
• Historically, Common Equity has averaged $186.7 million across 5 years, with a median of $45.0 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Common Equity plunged 173.86% in 2024, then jumped 5266.81% in 2025.
• A 5-year view of Common Equity shows it stood at $41.7 million in 2022, then retreated by 11.17% to $37.0 million in 2023, then soared by 932.47% to $382.2 million in 2024, then climbed by 23.47% to $471.9 million in 2025, then gained by 3.13% to $486.7 million in 2026.
• The last three Common Equity figures came in at $486.7 million (Q1 2026), $471.9 million (Q4 2025), and $486.8 million (Q3 2025), per Business Quant data.